| Title | Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer |
| Publication Type | Journal Article |
| Year of Publication | 2011 |
| Authors | Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W |
| Journal | JAMA : the journal of the American Medical Association |
| Volume | 306 |
| Pagination | 1557-65 |
| Date Published | Oct 12 |
| Type of Article | Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov't |
| PMID | 21990299 |
| Keywords | *Genes, BRCA1, *Genes, BRCA2, *Mutation, Adult, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology, Databases, Factual, Disease Progression, DNA Methylation, Drug Resistance, Neoplasm, Female, Genomic Instability, Humans, Middle Aged, Ovarian Neoplasms/drug therapy/*genetics/*mortality, Phenotype, Prognosis, Promoter Regions, Genetic, Survival Analysis, Treatment Outcome |
| Abstract | CONTEXT: Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results. OBJECTIVE: To determine the relationships between BRCA1/2 deficiency (ie, mutation and promoter hypermethylation) and overall survival (OS), progression-free survival (PFS), chemotherapy response, and whole-exome mutation rate in ovarian cancer. DESIGN, SETTING, AND PATIENTS: Observational study of multidimensional genomics and clinical data on 316 high-grade serous ovarian cancer cases that were made public between 2009 and 2010 via The Cancer Genome Atlas project. MAIN OUTCOME MEASURES: OS and PFS rates (primary outcomes) and chemotherapy response (secondary outcome). RESULTS: BRCA2 mutations (29 cases) were associated with significantly better OS (adjusted hazard ratio [HR], 0.33; 95% CI, 0.16-0.69; P = .003 and 5-year OS, 61% for BRCA2-mutated vs 25% for BRCA wild-type cases) and PFS (adjusted HR, 0.40; 95% CI, 0.22-0.74; P = .004 and 3-year PFS, 44% for BRCA2-mutated vs 16% for BRCA wild-type cases), whereas neither BRCA1 mutations (37 cases) nor BRCA1 methylation (33 cases) was associated with prognosis. Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively). BRCA2-mutated, but not BRCA1-mutated cases, exhibited a "mutator phenotype" by containing significantly more mutations than BRCA wild-type cases across the whole exome (median mutation number per sample, 84 for BRCA2-mutated vs 52 for BRCA wild-type cases, false discovery rate <0.1). CONCLUSION: Among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCA wild-type. |
| Short Title | JamaJama |
| Alternate Journal | Jama |
© 2012, Institute for Systems Biology, All Rights Reserved | TERMS OF USE | COI | INTRANET | LOGIN